RE:RE:RE:RE:RE:RE:RE:BP Boehringher Ingelheim to continue in Oncolytic VirusesRemodeling the TME and turning cold tumors "hot" has become a major focus of attention in Big Pharma's R&D activities.
ONCY has the clinical data resulting from the AWARE-1 study that demonstrates pelareorep's MOA in this regard.